These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9562828)

  • 1. Angiotensin II receptor blockers in hypertension and renal disease.
    Bakris GL
    Hosp Pract (1995); 1998 Apr; 33(4):19-22. PubMed ID: 9562828
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospective trials of angiotensin receptor blockers: beyond blood pressure control.
    Siragy HM; Carey RM
    Curr Hypertens Rep; 2000 Apr; 2(2):163-4. PubMed ID: 10981143
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiology patient page. Angiotensin receptor blockers.
    Terra SG
    Circulation; 2003 Jun; 107(24):e215-6. PubMed ID: 12821593
    [No Abstract]   [Full Text] [Related]  

  • 4. AT1-receptor blockers.
    Petkun W
    Eur Heart J; 2000 Feb; 21(4):335-7. PubMed ID: 10653684
    [No Abstract]   [Full Text] [Related]  

  • 5. Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL.
    Coats AJ
    Int J Cardiol; 2001 Jul; 79(2-3):99-102. PubMed ID: 11461726
    [No Abstract]   [Full Text] [Related]  

  • 6. [Efficacy-safety relationship of AT1 angiotensin II receptor antagonists: current data].
    Paoletti V; Di Veroli C; Pugliese M; Cammarella I; Cavina G; Turchetti P; Mammarella A
    Clin Ter; 2002; 153(1):61-4. PubMed ID: 11963637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension.
    Hedner T; Oparil S; Rasmussen K; Rapelli A; Gatlin M; Kobi P; Sullivan J; Oddou-Stock P
    Am J Hypertens; 1999 Apr; 12(4 Pt 1):414-7. PubMed ID: 10232502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fast-acting sartan. High blood pressure therapy without long waiting time].
    MMW Fortschr Med; 2003 Jun; 145(24):55. PubMed ID: 12866306
    [No Abstract]   [Full Text] [Related]  

  • 9. [Lowering blood pressure with sartans. Are there differences?].
    MMW Fortschr Med; 2002 Nov; 144(47):63. PubMed ID: 12532530
    [No Abstract]   [Full Text] [Related]  

  • 10. Valsartan treatment of hypertension--does VALUE add value?
    Lindholm LH
    Lancet; 2004 Jun; 363(9426):2010-1. PubMed ID: 15207946
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment with the angiotensin II antagonist valsartan in patients with chronic renal failure and hypertension.
    Plum J; Bünten B; Németh R; Grabensee B
    Nephrol Dial Transplant; 1999; 14 Suppl 4():25-7. PubMed ID: 10463202
    [No Abstract]   [Full Text] [Related]  

  • 12. Fetal toxic effects and angiotensin-II-receptor antagonists.
    Martinovic J; Benachi A; Laurent N; Daikha-Dahmane F; Gubler MC
    Lancet; 2001 Jul; 358(9277):241-2. PubMed ID: 11480433
    [No Abstract]   [Full Text] [Related]  

  • 13. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
    Lin JW; Chang CH; Caffrey JL; Wu LC; Lai MS
    Hypertension; 2014 May; 63(5):968-76. PubMed ID: 24516110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
    Miller AB; Srivastava P
    Cardiol Clin; 2001 May; 19(2):195-202, v. PubMed ID: 11407105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [spACE, the last frontier? Renin inhibition in hypertension].
    Villa L
    G Ital Nefrol; 2008; 25(3):274. PubMed ID: 18473295
    [No Abstract]   [Full Text] [Related]  

  • 16. Sartans for hypertension--implications of the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial.
    Cheung BM
    Hong Kong Med J; 2004 Oct; 10(5):359. PubMed ID: 15479968
    [No Abstract]   [Full Text] [Related]  

  • 17. Angiotensin type 1 receptor blockers in chronic kidney disease.
    Suzuki H
    Contrib Nephrol; 2004; 143():159-66. PubMed ID: 15248363
    [No Abstract]   [Full Text] [Related]  

  • 18. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial.
    Elliott WJ; Calhoun DA; DeLucca PT; Gazdick LP; Kerns DE; Zeldin RK
    Clin Ther; 2001 Aug; 23(8):1166-79. PubMed ID: 11558856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
    Smith DH; Dubiel R; Jones M
    Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palatability of angiotensin II antagonists among nephropathic children.
    Meier CM; Simonetti GD; Ghiglia S; Fossali E; Salice P; Limoni C; Bianchetti MG;
    Br J Clin Pharmacol; 2007 May; 63(5):628-31. PubMed ID: 17302913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.